{"prompt": "['Patients will be followed for death a minimum of 36 months after randomisation. Overall survival will be measured', 'from the time of randomisation until death. Medical records and death certificates will be reviewed every 6 months', 'to obtain survival status. Country-specific mortality status databases will also be searched annually; cause of', 'death will be determined through review of medical and death records. Patients will be contacted once a year,', 'and follow up with next of kin then alternate contact, if needed, if we do not hear from them.', '11.0 SECONDARY ENDPOINTS', '11.1 Disease progression', 'Data on disease progression will be obtained through review of patient medical records each cycle.', 'Progression will be determined by the treating physician, and may include any of the following, based on', 'PCWG-3 and RECIST 1.1 criteria:', '- Bone scan: Appearance of 2 new lesions on bone scan, if bone scan >12 weeks after randomisation', '- CT/MRI: 20% increase in the sum of diameters, taking the reference as the smallest sum on study. In', 'addition to the relative increase by 20%, the sum must also demonstrate an absolute increase >5 mm.', 'OR The appearance of one or more new lesions. OR Unequivocal progression of baseline unmeasurable', 'lesions (see further details below). If the patient has measurable disease, there must be overall worsening', 'in non-measurable disease such that the overall tumour burden has increased substantially. The', 'designation of disease progression solely on the basis of change in non-measurable disease in the face', 'of stable disease or partial response of the measurable disease is extremely rare.', '- Development of an indication for initiating a therapy for MCRPC after randomisation, including, but not', 'limited to, abiraterone, enzalutamide, chemotherapy, or radiation therapy.', '- Symptomatic-skeletal related event (SSE).', 'Progression free survival will be measured from randomisation until the first of the following: first CT or', 'bone scan documenting disease progression, initiation of a new therapy for MCRPC (clinical', 'progression), or first occurrence of a SSE.', '11.1.1 CT Scan Progression of Non-measurable Lesions', 'Progression will be defined based on PCWG;-3 and RECIST 1.1 as all other lesions, including small lesions', '(longest diameter <10mm or pathological lymph nodes 10-<15mm short axis) as well as truly non-measurable', 'lesions. All non-measurable lesions should be recorded at baseline. Measurements are not required and these', 'lesions should be followed as \"present\", \"absent\", or in rare cases, \"unequivocal progression.\" Multiple non-', 'measurable lesions involving the same organ should be recorded as a single item on the case report form (e.g.,', '\\'multiple enlarged pelvic lymph nodes\\' or \"multiple liver metastases\\').', '11.2 Symptomatic Skeletal Related Events', 'Time to first occurrence of SSE will be defined as the time from randomisation to documentation of any of the', 'following (whichever occurs first) + 1 day:', 'Use of external beam radiation therapy to relieve bone pain', 'Occurrence of new symptomatic pathological bone fractures that may be vertebral or non-vertebral.', 'Asymptomatic compression fractures detected by radiology review only will not be considered a SSE.', 'Spinal cord compression', 'Change in antineoplastic therapy to treat bone pain', 'Surgical intervention to treat bone pain', \"Adverse event, concomitant medication, concomitant treatment, or survival follow-up CRFs and the participant's\", 'medical record will be the source of these findings and presented as categorical data.', '11.3 Analgesic/Opiate Use', 'Analgesic/opiate use will be assessed via BPI-SF, the WHO analgesic scale, and medical record review at entry', 'INTERVAL Protocol Version 4.0, 19 April 2018', '39']['with a lead-in period (<28 days). The WHO analgesic scale will be completed every three cycles (based on', 'medical review) and questionnaires will be administered every three cycles until month 24, and yearly thereafter.', '11.4 Metabolic Biomarkers', 'Initial investigations will focus on analysis of biomarkers at selected time points; it is envisioned that additional', 'funding will be acquired for investigation of additional time points.', 'Inflammatory and cytokine systemic milieu: Serum/plasma aliquots (baseline and cycle 6) from all Arm A and', 'B patient samples are intended for interrogation of a panel of markers associated with inflammation including', 'IL1B, IL-2, IL-6, TNFa and adiponectin. These samples may be run in single or multiplex reactions as appropriate', 'using a commercial platform such as MesoScale Diagnostics. Results from these investigations will be correlated', 'with c-reactive protein and measured outcomes of exercise response and disease progression.', 'Insulin/Glucose Metabolism: Serum aliquots (baseline and cycle 6) from all Arm A and B patient samples are', 'intended for assessment of insulin levels by e.g. enzyme-linked immunosorbent assay (ELISA). Insulin sensitivity', 'will be calculated using these fasting serum insulin values and plasma glucose determinations obtained in the', 'additional clinical blood assessments, where the HOMA-IR method will be applied. C-peptide will also be', 'assessed in all samples and used to monitor glucose levels longitudinally in both the intervention and control', 'groups. Additional assays for IGF-1 will also be performed.', 'Androgen biosynthesis: Serum aliquots from all Arm A and B patient samples at baseline are intended for', 'assessment of androgen levels (Testosterone, DHT, androstenedione, DHEA, 17-hydroxyprogesterone, 17-', 'hydroxypregnenolone and progesterone) levels by mass spectrometry (MS). Previous studies using this assay', 'have demonstrated results in a lower limit of quantitation of 1 pg per sample for testosterone and DHT,', 'respectively. Intra-assay coefficients of variation generated using human serum for high-, mid-, and low-range', 'samples were 3.5%, 3.1%, and 3.8% for testosterone and 6.3%, 4.3%, and 15.8% for DHT, respectively.', '11.5 Physical Function', 'Physical function will be assessed using strength assessments (1RM), a cardiopulmonary exercise test (CPET)', 'and a functional performance test (400m walk). Strength assessments will be quantified in kilograms lifted, and', 'will be dependent upon the location and size of bone metastatic lesions present as to which tests are performed', '(Chest Press, Leg Press, Seated Row and Leg Extension). All strength assessments should be attempted if not', 'contraindicated. Cardiopulmonary exercise capacity will be quantified by VO2peak (L.min and mL/(kg-min)) and', 'workload achieved (watts) during a successful CPET (RPE 9). Functional performance will be represented by', 'time (in seconds) taken to perform a 400m walk test.', '11.6 Quality of Life', 'Symptoms will be considered independently of other outcome measures. Pain will be assessed via BPI-SF', 'and', 'medical record review at entry with a lead-in period (<28 days) and repeated measures will occur every three', 'cycles. Changes occurring within 12 weeks of study initiation will be ignored in the absence of compelling', 'evidence of disease progression. Response or progression of pain will be confirmed through repeat assessments', 'separately by at least three weeks. Quality of life measured by the FACT-G, FACIT-Fatigue, QLQ-C30, EPIC-', '26, and EQ5D will be assessed every 3 cycles.', '12.0 STATISTICAL CONSIDERATIONS', '12.1 Enpoints', 'Our primary endpoint is OS. Secondary endpoints include PFS, pain, opiate use, cancer-related fatigue,', 'symptomatic SSE, and QOL-adjusted OS. OS will be measured from the date of randomisation to date of death', 'due to any cause.', '12.2 Power and Sample Size for Primary Endpoint', 'This is a 1:1 randomised controlled trial in men with MCRPC. Registered and eligible participants will be', 'INTERVAL Protocol Version 4.0, 19 April 2018', '40']\n\n###\n\n", "completion": "END"}